OncoCyte (NASDAQ:OCX - Get Free Report)'s stock had its "buy" rating reaffirmed by research analysts at Needham & Company LLC in a research report issued on Tuesday,Benzinga reports. They currently have a $4.25 price objective on the stock. Needham & Company LLC's price target indicates a potential upside of 51.25% from the stock's current price.
A number of other research analysts have also commented on OCX. StockNews.com started coverage on OncoCyte in a research note on Sunday, April 6th. They issued a "sell" rating for the company. Stephens restated an "equal weight" rating and issued a $4.00 price objective on shares of OncoCyte in a research note on Tuesday, March 25th. Finally, Lake Street Capital initiated coverage on shares of OncoCyte in a report on Friday, March 28th. They set a "buy" rating and a $5.00 price objective for the company.
Check Out Our Latest Stock Analysis on OCX
OncoCyte Stock Performance
Shares of OCX opened at $2.81 on Tuesday. The company has a 50-day simple moving average of $3.16 and a 200-day simple moving average of $2.70. OncoCyte has a 52 week low of $1.92 and a 52 week high of $4.75. The firm has a market capitalization of $80.36 million, a P/E ratio of -0.64 and a beta of 0.95.
OncoCyte (NASDAQ:OCX - Get Free Report) last posted its quarterly earnings results on Monday, May 12th. The company reported ($0.26) EPS for the quarter. OncoCyte had a negative net margin of 6,122.29% and a negative return on equity of 269.32%. As a group, equities analysts forecast that OncoCyte will post -2.57 earnings per share for the current year.
Institutional Trading of OncoCyte
Institutional investors have recently bought and sold shares of the stock. Ground Swell Capital LLC bought a new position in shares of OncoCyte during the fourth quarter valued at $26,000. Two Sigma Securities LLC acquired a new stake in shares of OncoCyte during the 4th quarter worth about $31,000. FNY Investment Advisers LLC lifted its holdings in OncoCyte by 15.1% during the 4th quarter. FNY Investment Advisers LLC now owns 49,377 shares of the company's stock valued at $117,000 after purchasing an additional 6,481 shares during the last quarter. Wealthedge Investment Advisors LLC bought a new position in OncoCyte during the 4th quarter valued at about $126,000. Finally, Geode Capital Management LLC boosted its position in OncoCyte by 12.2% in the third quarter. Geode Capital Management LLC now owns 103,980 shares of the company's stock valued at $296,000 after buying an additional 11,289 shares in the last quarter. Institutional investors and hedge funds own 55.35% of the company's stock.
OncoCyte Company Profile
(
Get Free Report)
OncoCyte Corporation, a precision diagnostics company, focuses on development and commercialization of proprietary tests in the United States and internationally. The company is developing DetermaIO, a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies; DetermaCNI, a blood-based monitoring tool for monitoring therapeutic efficacy in cancer patients; and VitaGraft, a blood-based solid organ transplantation monitoring test.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider OncoCyte, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and OncoCyte wasn't on the list.
While OncoCyte currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.
Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
